Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. reported operational and financing disclosures in its Form 10-Q, including capital structure, third-party agreements and program cost changes. The company noted Emergency Use Authorization for PEMGARDA in March 2024 and that sales of PEMGARDA have funded operations. During the period the company sold 9,000,000 shares under an at-the-market facility for net proceeds of $39.3 million at an average price of $4.50 per share and had $325 million of securities remaining on its shelf registration as of June 30, 2025. A $30 million Term Facility is available in three tranches subject to financial covenants and net product revenue milestones; as of June 30, 2025 the company had not met the revenue milestone required to draw on the earliest tranche. Material contractual items include significant Adimab obligations (quarterly fees of $0.6 million and royalty terms, including 45%–55% on certain compulsory sublicenses), lease liabilities of $1.1 million (current) and $1.9 million (non-current), and stock plans and equity awards including 1,700,000 RSUs granted at $1.61 per share.
Invivyd, Inc. filed a current report describing several disclosures made on August 14, 2025. The company issued a press release with its financial results for the quarter ended June 30, 2025 and recent business highlights, which is included as Exhibit 99.1.
Invivyd also released a separate press release titled “Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19,” filed as Exhibit 99.2. In addition, the company posted an updated corporate presentation on its website, furnished as Exhibit 99.3.
This Schedule 13G/A discloses that Maverick Capital, Ltd., Maverick Capital Management, LLC and Lee S. Ainslie III report beneficial ownership of 10,229,118 shares of Invivyd, Inc., representing 8.5% of the 119,961,445 outstanding shares reported as of May 1, 2025. The filing identifies the shares as held for Maverick clients across five funds: Maverick Fund USA, Ltd. (2,253,369), Maverick Fund II, Ltd. (2,210,410), Maverick Long Enhanced Fund, Ltd. (2,419,202), Maverick HP, L.P. (2,139,246) and Maverick Long Fund, Ltd. (1,206,891).
Each reporting person states shared voting and dispositive power over these shares and no sole voting or dispositive power. The document is filed as a Schedule 13G (Amendment No. 2) and includes a certification that the securities were not acquired to change or influence control of the issuer. The filing lists Maverick's Dallas, TX address and Mr. Ainslie's West Palm Beach, FL address and is signed on 08/14/2025.
Invivyd, Inc. (Nasdaq: IVVD) filed an 8-K to disclose that, on July 2, 2025, it issued a press release announcing the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group. The collaboration brings Invivyd together with leading researchers to evaluate the effects of the company’s monoclonal antibody therapy on two patient populations: 1) individuals suffering from Long COVID and 2) those experiencing COVID-19 post-vaccination syndrome.
The filing contains no financial results, trial data, or guidance. Instead, it simply furnishes the press release as Exhibit 99.1 under Item 8.01 (Other Events) and lists customary exhibit and signature information.
Invivyd (Nasdaq: IVVD) filed an 8-K under Item 8.01 to furnish a press release dated 26 June 2025.
The release reports positive full Phase 1/2 clinical data for VYD2311, a next-generation COVID-19 monoclonal antibody being pursued for both non-vaccine prophylaxis and treatment of active infection.
The document attaches the press release as Exhibit 99.1; no financial statements, guidance changes, or other material corporate actions were disclosed.